The Claim
The loss of lean body mass induced by glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors is proportionally similar to that observed with diet-induced weight loss, indicating that negative energy balance is the primary driver of lean mass reduction rather than unique pharmacological toxicity.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Weight loss from GLP-1 receptor agonists and SGLT2 inhibitors reduces lean body mass at the same rate as weight loss from dieting, suggesting that the reduction is due to overall calorie deficit, not direct drug effects on muscle tissue.
See the scientific wording
The loss of lean body mass induced by glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors is proportionally similar to that observed with diet-induced weight loss, suggesting that the mechanism of lean mass reduction is primarily driven by negative energy balance rather than unique pharmacological toxicity.
When the body burns more calories than it takes in, it breaks down muscle tissue to get amino acids for making glucose and energy. This happens whether the calorie deficit comes from eating less or from losing glucose in urine, and the amount of muscle lost is the same in both cases.
What the research says
1 studyWhen people lose weight with these drugs, they lose about the same amount of muscle as when they lose weight by eating less — meaning the drugs aren’t specially hurting muscle; it’s just a normal side effect of losing weight.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.